Issue 6/2012

  • Obama’s new biobased economy

    In this issue:

    • Cover Story: Obama’s new biobased economy - The bioeconomy begins to go truly global
    • GSK absorbs Cellzome; German biotech sector expanding
    • Abbott buys kidney treatment from Action Pharma
    • DSM enters biomedicine with takeover of Kensey Nash
    • SPECIAL: BiobasedWorld at Achema – The guide to the trade fair
    • Zeltia pockets Yondelis milestone from Johnson & Johnson
    • Selvita stuffs its war-chest with shares, grants and awards
    • Pattern of DNA methylation determines genome stability

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/6/pos/1.html?sort=asc&cHash=bfd90e2d54056358af1b4a091bcb4f71

Kurszettel

Alle Kurse

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.55 CHF99.3%
  • ADDEX (CH)4.08 CHF85.5%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-29.1%
  • PROSENSA (NL)9.48 USD-26.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP780.4%
  • PAION (D)2.79 EUR304.3%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.48 USD-68.2%

No liability assumed, Date: 24.07.2014